halipeptin A: 17-membered cyclic depsipeptide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10438962 |
| CHEMBL ID | 3814928 |
| MeSH ID | M0411615 |
| Synonym |
|---|
| halipeptin a |
| CHEMBL3814928 |
| (1r,4s,7s,10s,14s)-4-[(2s)-4-hydroxybutan-2-yl]-10-[(2r,5s)-5-methoxyoctan-2-yl]-1,3,7,11,11,14-hexamethyl-9-oxa-16-thia-3,6,13,18-tetrazabicyclo[13.2.1]octadec-15(18)-ene-2,5,8,12-tetrone |
Halipeptin A is a novel 17-membered cyclic depsipeptide. It consists of five residues including two alanines (with L stereochemistry)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Halipeptin A is a novel 17-membered cyclic depsipeptide, consisting of five residues including two alanines (with L stereochemistry) and three new residues that appear to be previously undescribed from natural sources: 1,2-oxazetidine-4-methyl-4-carboxylic acid, 3-hydroxy-2,2,4-trimethyl-7-methoxydecanoic acid (HTMMD), and N-methyl-delta-hydroxyisoleucine." | ( Halipeptins A and B: two novel potent anti-inflammatory cyclic depsipeptides from the Vanuatu marine sponge Haliclona species. Bifulco, G; Bucci, M; Cirino, G; Debitus, C; Giannini, C; Gomez-Paloma, L; Randazzo, A, 2001) | 1.03 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1304575 | Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 0.3 mg/kg, ip by hydroplethismometer | 2016 | Journal of natural products, Mar-25, Volume: 79, Issue:3 | The Halicylindramides, Farnesoid X Receptor Antagonizing Depsipeptides from a Petrosia sp. Marine Sponge Collected in Korea. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.33) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||